WEBULL
WebtradeDownload

NeoGenomics (NEO) CEO Handover And Guidance Lift Put Valuation Back In Focus

Simply Wall St · 2d ago

NeoGenomics (NEO) is back in focus after the board mapped out a CEO handover to current President and COO Warren Stone and reaffirmed and then flagged an expected lift to full year revenue guidance.

Recent trading suggests interest is building again in NeoGenomics, with a 1-day share price return of 2.84% and a 90-day gain of 14.90%, even though the 30-day share price return is down 3.81% as investors digest the succession plan, updated guidance and the bylaw change expanding board capacity.

At a latest share price of US$16.66, the stock has delivered a 41.67% year to date share price return and a 77.61% total shareholder return over 1 year, while the 5-year total shareholder return is down 63.29%, which leaves recent momentum looking stronger than the longer term record.

Scan how other cancer testing and healthcare diagnostics stocks are reacting to leadership shifts and fresh guidance by reviewing our curated list of 33 healthcare AI stocks alongside NeoGenomics today.

NeoGenomics has rebounded sharply following the CEO handover and stronger NGS revenue, yet its 5-year record remains weak. Investors may be considering whether it makes more sense to commit at US$16.66 or to wait for a potentially more attractive entry point as the valuation case develops.

Most Popular Narrative: 21% Undervalued

NeoGenomics is trading at $16.66 against a widely followed fair value estimate of $21.15. This frames the recent rebound as investors reassessing future earnings power rather than just reacting to the CEO handover.

Investments in new digital pathology capabilities, automation, and the integration of a unified LIMS are expected to generate material operating efficiencies and enable greater operating leverage. These initiatives may support future expansion in EBITDA margins and earnings growth. Successfully renegotiated managed care agreements and ongoing reimbursement initiatives are improving revenue predictability and mix, with test menu expansion (including new NGS and MRD offerings) enhancing revenue per patient and providing a basis for potential long-term, above-market earnings growth.

See why 6 investors see NeoGenomics as 21% undervalued.

Result: Fair Value of $21.15 (UNDERVALUED)

Still, the narrative around NeoGenomics could falter if pharma and biotech demand stays weak or if legal and IP disputes around key platforms escalate.

Find out about the key risks to this NeoGenomics narrative.

Another View: NeoGenomics Looks Expensive On Sales

The fair value narrative paints NeoGenomics as about 21% undervalued at $21.15, yet its P/S of 2.8x sits far above both the US Healthcare sector at 1.3x and an estimated fair ratio of 1.5x. That gap points to valuation risk rather than a clear bargain. Which story do you trust more?

See what the numbers say about this price — find out in our valuation breakdown.

NasdaqCM:NEO P/S Ratio as at Oct 2026
NasdaqCM:NEO P/S Ratio as at Oct 2026

Next Steps

Conflicted by NeoGenomics looking undervalued on some models yet expensive on simple sales metrics? Move quickly from headline narratives to your own conclusion by stress testing both views against the underlying risk profile and reviewing the 2 important warning signs.

Looking for more NeoGenomics investment ideas?

If NeoGenomics has sharpened your focus, do not stop here. Broader context matters, and the right comparison set can reshape how you see any single ticker.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.